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ABSTRACT 
 
 
 
 
Apolipoprotein-D (apoD) is expressed in the brain and levels are increased in affected brain 
regions  in  Alzheimer’s  disease  (AD).  The  role  that  apoD  may  play  in  regulating  AD 
pathology has not been addressed. Here we crossed both apoD null mice and Thy-1 human 
apoD transgenic mice with APP-PS1 amyloidogenic AD mice. Loss of apoD resulted in an ~ 
2-fold increase in hippocampal amyloid plaque load assessed by immunohistochemical 
staining. Conversely, transgenic expression of neuronal apoD reduced hippocampal plaque 
load by ~ 35%. This latter finding was associated with a 60% decrease in amyloid-beta 1-40 
peptide levels, and a 34% decrease in insoluble amyloid-beta 1-42 peptide. Assessment of 
beta-site amyloid precursor protein cleaving enzyme-1 (BACE1) levels and proteolytic 
products of amyloid precursor protein and neuregulin-1 point towards a possible association 
of altered BACE1 activity in association with altered apoD levels. In conclusion, the current 
studies provide clear evidence that apoD regulates amyloid plaque pathology in a mouse 
model of AD. 
 
 
 
Keywords: Apolipoprotein-D, Alzheimer’s disease, amyloid-pathology, amyloid-β, 
neurodegeneration. 
 
 
 
Abbreviations:  A, amyloid-beta peptide; AD, Alzheimer’s disease; apoD, apolipoprotein- 
D; BACE1, beta-site amyloid precursor protein cleaving enzyme-1; BCA, bicinchoninic acid; 
BHT, butylated hydroxytoluene; CTFs, C-terminal fragments; DKO, apoD gene knockout 
mice; DTG, human apoD transgenic mice; L-OOH, lipid hydroperoxide; MTBE, Methyl-tert- 
butyl ether; ThS, thioflavine S 
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1. Introduction 
 
 
 
 
 
ApoD is expressed in the brain and levels are increased during brain development and aging 
(Kim et al., 2009). It is also established that apoD levels are increased in affected brain 
regions in Alzheimer’s disease (AD) and in AD mouse models (Bhatia et al., 2013; Terrisse 
et al., 1998; Thomas et al., 2003; Thomas et al., 2001). Additional studies show that brain 
lipid peroxidation is increased during aging (Cristiano et al., 1995; Droge and Schipper, 
2007), as well as in AD and AD mouse models (Abdul et al., 2008; Markesbery and Carney, 
 
1999; Montine et al., 2007; Sayre et al., 1997; Schuessel et al., 2005). Furthermore, recent 
studies show that the increase in apoD associated with aging and AD in human brain tissues 
is correlated with markers of lipid oxidative stress (Bhatia et al., 2013; Kim et al., 2009). 
These findings are particularly pertinent as a novel role for apoD in the control of brain lipid 
peroxidation has been reported (Bajo-Graneras et al., 2011; Bajo-Graneras et al., 2011; 
Ganfornina et al., 2008). Studies in mice revealed that brain apoD is induced in response to 
oxidative stress, that lipid peroxidation is increased in the brains of apoD null mice, and that 
neuronal  expression  of  human  apoD  prevents  brain  lipid  peroxidation  in  response  to 
paraquat-induced oxidative stress (Ganfornina et al., 2008). 
 
 
 
 
 
One mechanism by which apoD acts as a lipid antioxidant involves the interaction of a single 
conserved Met residue located within the hydrophobic patch at the entrance of the apoD 
ligand binding pocket (Bhatia et al., 2012; Oakley et al., 2012). The apoD Met93 residue 
interacts directly with potentially reactive radical-generating lipid hydroperoxide (L-OOH) 
species, converting them to non-reactive lipid hydroxides, an antioxidant activity that is lost 
when Met93 is replaced with Ala (Bhatia et al., 2012). One consequence of this reaction is the 
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formation of a Met-sulfoxide residue that destabilizes the protein and promotes its non- 
covalent dimerization (Bhatia et al., 2012). Interestingly, apoD dimers have been identified in 
the hippocampus, but not in the pathologically spared cerebellum, of human AD subjects 
(Bhatia et al., 2013). There is now a growing consensus that apoD may play a protective role 
in AD, and other neurological diseases (Bhatia et al., 2013; Dassati et al., 2014). 
 
 
 
 
 
One  important  question  that  remains  unanswered  centres  on  the  postulated  protective 
function of apoD in AD and whether it could modulate pathological processes (including 
those associated with amyloid plaque pathology and lipid peroxidation) or simply represent a 
marker of disease progression. Based on the studies cited above, we hypothesized that apoD 
gene deletion may exacerbate the AD phenotype in amyloidogenic AD mice whereas early 
over-expression of apoD in neurons would have the opposite effect, and reduce the AD 
amyloidogenic phenotype. In the current study we have addressed this hypothesis by crossing 
apoD  null  mice,  as  well  as  transgenic  mice  expressing  human  apoD  in  neurons,  with 
APP/PS1 amyloidogenic mice and assessing for possible alterations in amyloid plaque load 
and markers of brain lipid peroxidation. 
 
 
 
 
2. Materials and Methods 
 
 
 
 
2.1. Materials 
 
 
 
 
Methyl-tert-butyl ether (MTBE), chloroform and methanol were HPLC grade and purchased 
from Thermo Scientific, Scoresby, VIC, Australia. Analytical grade ammonium acetate was 
from Crown Scientific, Moorebank, NSW, Australia. Screw thread vials (4 mL) and wide 
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mouth vials (1.8 mL) with PTFE/silicone septa caps were from Grace Davison, Rowville, 
VIC, Australia. The internal lipid standard mixture contained AA (Avanti Polar Lipids 
purchased from Auspep, Tullamarine, VIC, Australia) and F2-isoprostanes in 
chloroform/methanol (2:1, vol:vol). F2-isoprostanes F2III-ISP (8-iso-prostaglandin F2) and 
F2VI-ISP  (5S,9,11,-trihydroxy-1,1,1-trihomo-18,19,20-trinor-8-prosta-2Z,6E-dien- 
1-oic acid) were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Other reagents 
 
including analytical  grade butylated hydroxytoluene (BHT) and sodium hydroxide (98% 
 
minimum) were from Sigma Aldrich, Sydney, NSW, Australia. 
 
 
 
 
2.2. Transgenic mice 
 
 
 
 
Three strains of mice were used to generate amyloidogenic AD mice with either increased 
neuronal expression of apoD or a complete lack of apoD. We used the APP-PS1 AD mouse 
model expressing chimeric mouse/human APP695swe/Swedish mutations (K595N/M596L) 
and mutant human PS1 (PS1/∆E9) obtained from the Jackson Laboratory (Bar Harbor, USA; 
Strain name, B6.Cg-Tg AβPPswePSEN1dE9)85Dbo/J; Stock #005864) and maintained as 
double hemizygotes on a C57BL/6J background as described previously (Cheng et al., 2013; 
Jankowsky et al., 2004). This AD mouse model is on a pure (backcrossed > 10 generations) 
C57BL6  background  and  has  well  characterised  plaque  pathology  (Garcia-Alloza  et  al., 
2006). These mice have a pronounced AD phenotype with amyloid deposits by 6 months of 
age which is accompanied by neuron loss and hippocampal atrophy by 12 months (Garcia- 
Alloza et al., 2006). The generation and characterisation of the apoD gene knockout (DKO) 
mice and the human apoD transgenic (DTG) mice (DTG mice selectively expresses human 
apoD in neurons under the control of the Thy-1 promoter) was previously described 
(Ganfornina et al., 2008). The neuron-specific expression of human apoD in the DTG mice 
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has been established (Do Carmo et al., 2008; Ganfornina et al., 2008). Hemizygous APP-PS1 
mice were crossed with either DKO or DTG mice to generate APP-PS1/DKO+/-  and APP- 
PS1/DTG+/-   breeders.  These  mice  were  used  to  generate  APP-PS1/DKO+/+   and  APP- 
PS1/DTG+/+ and littermate APP-PS1 control groups. As previously described (Jankowsky et 
 
al., 2004), the expression of the human mutant AβPPswe and PSEN1dE9 segregate together. 
 
All test animals were hemizygous with respect to the AβPPswe and PSEN1dE9 transgenes, in 
 
line with standard protocols for amyloidogenic AD mouse models (Gotz and Ittner, 2008; 
 
Higgins and Jacobsen, 2003). All mice were on a pure (backcrossed > 10 generations) 
C57BL6 background. Genotyping of the APP-PS1, DKO and DTG mice has been described 
previously (Ganfornina et al., 2008; Kim et al., 2010). Test animals were females at ~11 
months of age (DKO Study: APP-PS1, n = 9, 49.7 ± 4.7 weeks old; APP-PS1/DKO n = 7, 
50.7 ± 4.3 weeks old; DTG Study: APP-PS1, n = 8, 44.2 ± 1.6 weeks old; APP-PS1/DTG n = 
 
7, 44.2 ± 2.1 days old). Female APP-PS1 mice were used as they accumulate a more sever 
 
amyloid pathology at an early age compared to male APP-PS1 mice (Wang et al., 2003). 
Ethics approval was from the University of Wollongong and the University of New South 
Wales animal ethics committees. 
 
 
 
2.3. Tissue preparation 
 
 
 
 
Mice were euthanized by CO2  asphyxiation and transcardially perfused with ice-cold 
phosphate buffered saline (PBS). The brains were removed and sagittally divided and the 
hippocampus dissected from the right hemisphere before snap freezing and storage at -80˚C. 
The left hemisphere was immersion fixed in 4% paraformaldehyde in 0.1 M phosphate buffer 
(PB) at 4˚C for three days, then preserved in 30% (w/v) sucrose in 0.1M PB with 0.01% 
sodium azide at 4˚C until sectioning. Six sets of 45 m sagittal cryo-sections were collected 
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and stored at -20˚C in antifreeze solution for histological and immunohistochemiical analysis. 
One part of pulverized hippocampus (~15mg) was homogenized in 10 volumes of 140 mM 
NaCl, 3 mM KCl, 25 mM Tris (pH 7.4), containing 1% Nonidet P-40 and Roche complete 
protease inhibitors (TBS/NP40 extraction buffer) using a Precellys 24 homogenizer (2 x 30s, 
6000 g). Homogenates were centrifuged at 20,817 g for 15 min at 4˚C and the TBS/NP40- 
soluble supernatant aliquoted into several tubes and stored at −80˚C until use in western 
blotting and ELISA experiments. Protein concentration was measured using the bicinchoninic 
acid (BCA) method. 
 
 
 
2.4. PCR 
 
 
 
 
Mouse genotyping was assessed on DNA extracted from tail tips using the ISOLATE 
Genomic DNA mini kit (BIO-52032, Bioline Sydney, Australia) as described previously 
(Borchelt et al., 1996; Do Carmo et al., 2009; Ganfornina et al., 2008). For brain mRNA 
analysis, total RNA from the cortex was extracted using TriReagent and RNA concentrations 
determined  using  a  Nanodrop  1000  spectrophotometer  (Thermo  Fisher  Scientific)  and 
260/230 nm and 260/280 nm absorbance ratios used to determine RNA purity. Two μg of 
total RNA was used for reverse transcription with oligo dT(18) primers using the Tetro 
cDNA Synthesis kit (Bioline, Sydney, Australia). For apoD mRNA validation, PCR was 
conducted on an Eppendorf Master cycler or a Bio-Rad Thermalcycler using My Taq HS Mix 
(Bioline, Sydney, Australia) with the following primer pairs: human apoD: forward, 5' - TGC 
AGG AGA ATT TTG ACG TG - 3', reverse, 5' - AGG TTA ACT GGG GTG GCT TC - 3'; 
mouse apoD: forward, 5' - CCA CCG GCA CCC TAC TGG ATC - 3', reverse, 5' - CGG 
GCA GTT CGC TTG ATC TGT - 3'. The PCR amplicons separated in 2% agarose gels were 
visualized using by Gel Logic 212 Pro image system (Carestream Health, Inc. NY, USA). 
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Mouse apoE mRNA analysis was carried out in a Roche Lightcycler 480 real-time PCR 
system using SensiFAST SYBR No-ROX kit (Bioline, Sydney, Australia), following the 
manufacturer's protocol with primer pairs:  forward, 5'- AAC AGA CCC AGC AAA TAC 
GCC - 3', reverse, 5' - CTC ATT GAT TCT CCT GGG CC - 3'. The level of apoE expression 
was calculated using the comparative threshold cycle (Ct) value method using the formula 
2−ΔΔCt. 
 
 
 
 
2.5. A ELISA 
 
 
 
 
A40  and  A42  in  TBS/NP40-soluble  hippocampal  homogenates  were  quantified  using 
 
ELISA kits (Cat #SIG-38954 and SIG-38956,  Covance, North Ryde NSW, Australia or 
 
EZBRAIN-SET, EMD Millipore Corporation, Billerica, MA, USA) following the 
 
manufacturer's  instructions  as  described  (Kim  et  al.,  2013).  The  insoluble  hippocampal 
 
homogenate fractions were prepared by centrifugation of TBS/NP40-soluble hippocampal 
 
homogenates at 20,817 x g for 15 min at 4°C and the pellet was homogenized with 6 volumes 
 
of 6.25 M guanidine HCl (gHCl) and assayed by ELISA, as previously described in detail 
 
(Kim  et  al.,  2013),  to give an estimate of “insoluble” A40  and  A42  levels  in  the 
 
hippocampus. Samples were diluted 1:10 (Aβ40) or 1:50 (Aβ42) and assayed in duplicate. 
Aβ40 and Aβ42 levels in extracts were calculated by comparing samples to the Aβ standard 
curves. 
 
 
 
2.6. Plaque histology 
 
 
 
 
Staining of hippocampal tissues with thioflavine S (ThS) and anti-A monoclonal antibody 
 
6E10 was performed as described previously (Kim et al., 2013). In brief, sagittal sections (45 
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m thick, free floating) were rinsed extensively with TBS to remove cryo-protectants and 
immersed in distilled H2O (2 min), Harris hematoxylin (2 min), distilled H2O (3 min), 1% 
(w/v) ThS (Sigma T1892, 3 min), distilled H2O (3 min), 1% (v/v) acetic acid (20 min), 
 
distilled H2O (3 min), and mounted in buffered glycerol. Three sections per mouse were 
 
analysed from the cortical and hippocampal regions between lateral 1 mm to lateral 2 mm 
 
from the midline as defined using a mouse brain atlas (Franklin and Paxinos, 2007). Images 
were captured using a Nikon TE2000 microscope equipped with a SPOT digital camera 
(Diagnostic Instruments) and Image-Pro Plus 6.1 software (Media Cybernetics, Silver Spring 
MD, USA). Hippocampal ThS-positive plaque load was quantified as percentage coverage of 
the area of interest (measured as μm2) using ImageJ. Data are presented as relative values 
compared to the relevant control group (which was arbitrarily assigned a value of 1.0). 
 
 
 
For amyloid plaque immunohistochemistry, sections were pre-treated with 95% formic acid 
for 5 minutes, rinsed with tap water, then quenched with 1% H2O2 for 30 min. After blocking, 
sections were incubated with biotin-6E10 monoclonal antibody (1:5000, Cat# SIG-39340, 
Covance,), for 16 h at 4˚C, followed by streptavidin-HRP (Sigma,S2438, 1:4000), 1 h at 
22˚C. The sections were developed using DAB substrate (SK-4105, Vector Laboratories) and 
scanned at 20X magnification (Aperio Digital Pathology System, Aperio Technologies). The 
percentage of the area occupied by immunoreactive products above background staining was 
measured in the hippocampal region (three sections per mouse, between lateral 1 mm to 
lateral 2.5 mm from the midline) using ImageJ software. Data are presented as relative values 
compared to the relevant control group (which was arbitrarily assigned a value of 1.0). 
 
 
 
 
2.7. Immunohistochemistry methods for apoD, BACE1, GFAP and Iba1 staining 
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After removal of cryo-protectants, consecutive sets of sagittal sections (45 μm thick) from the 
 
different  mouse  groups  were  immunostained  for  BACE1,  GFAP  and  Iba1  with  the 
 
peroxidase-3,3′-diaminobenzidine  (DAB)  method  as  previously  described  for 
 
immunohistochemistry (Kim et al., 2013). Briefly, sections were treated with 1% H2O2  in 
 
PBS for 30 minutes after antigen retrieval by boiling the sections in citrate buffer (0.01M, pH 
 
6.0 for 5min). Sections were then pre-incubated in 5% horse serum in PBS with 0.5% Triton 
 
X-100 for 1 h, and then incubated with the primary antibodies at 4˚C overnight (BACE1 
 
1:400, rabbit monoclonal, Cat# 5606, Cell Signalling; GFAP, 1:2000, rabbit polyclonal Cat# 
 
Z0334,  DAKO;  Iba1,  1:2000, rabbit polyclonal,  Cat# 019-19741,  Wako). Sections were 
 
further reacted with a biotinylated pan-specific secondary antibody (goat anti-rabbit IgG, 
 
Cat#  B7398,  Sigma)  at  1:200  for  2  h, and subsequently with Streptavidin−Peroxidase 
 
Polymer (1:5000, Sigma Cat# S2438) for 1 h. Immunoreaction product was visualized in 
 
SIGMAFAST™ DAB with Metal Enhancer (Cat# D0426). The mounted slides were scanned 
 
at 20X magnification with Aperio Digital Pathology System (Aperio Technologies, USA). 
 
 
 
 
The methods used for apoD immunofluorescence detection were as described previously 
 
(Lagares et al., 2007; Li et al., 2007). In brief, free-floating sagittal brain sections from WT, 
 
APP-PS1, APP-PS1/DTG mice were probed using an antibody raised against human apoD 
 
(1:400, clone EPR2916, rabbit monoclonal Cat# Ab108191, Abcam) alone, or with anti- 
 
NeuN  (1:500,  Clone  A60,  mouse  monoclonal  Cat#  MAB377,  EMD-Millipore)  double- 
 
staining to localize apoD in neurons. Another set of sections from APP-PS1/DKO mice were 
 
used for double-labelling with an A antibody (WO2 hybridoma culture media, 1:50, gift or 
 
Dr Qiao-Xin Li and Prof Colin Masters, University of Melbourne). Where indicated, the 
 
additional  antibodies  (BACE1  1:500,  GFAP  1:2000,  Iba1  1:1000)  were  also  included. 
 
Donkey anti-rabbit Alexa flour 488 (1:250, Cat# A-21206, Life Technologies) and donkey 
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anti-mouse IgG conjugated Alexa flour-594 (1:500, Cat# A-21203, Life Technologies) were 
 
used as the secondary antibodies. After mounting with anti-fade media (Cat#10981, Sigma), 
 
coverslips were sealed with nail polish, and the samples were stored at 4˚C. Images were 
 
captured using 4X and 10X objective lens (with an ocular lens at 10X) in a Nikon TE2000 
 
microscope equipped with a SPOT digital camera (Diagnostic Instruments) and Image-Pro 
 
Plus 6.1 software (Media Cybernetics, Silver Sprin MD, USA). High-power images were 
 
taken using a  Leica TCS SP5 confocal laser-scanning microscope (Leica Microsystems, 
 
Germany).   Optical   density   in   the   area   of   interest   was   measured   using   ImageJ 
 
(http://rsb.info.nih.gov/ij/)  as  described  previously  (Kim  et  al.,  2013),  using  freehand 
 
selection to outline hippocampal and cortical regions (sampling section immunolabelling 
 
tools). Data were compared to appropriate control mouse groups for both the DKO and DTG 
 
groups and statistical differences were assessed using the student’s t-test where P < 0.05 was 
 
considered significant. 
 
 
 
 
2.8. Western blotting 
 
 
 
 
TBS/NP40-soluble homogenates were analysed by SDS-PAGE (~15 to 50 μg protein per 
 
lane) and western blotting using antibodies to: apoD (sc-34760 or sc-166612, Santa Cruz, 
 
1:5000), apoE (Cat# 178479, Merck Millipore, 1:5,000), APP (WO2 monoclonal provided by 
Dr Qiao-Xin Li and Prof Colin Masters, University of Melbourne, 1:200), APP C-terminal 
fragments (A8717, Sigma, 1:10,000), BACE1 (Ab108392, clone EPR3956, Abcam, 1:5,000) 
NRG-1 C-terminal fragments (SC-348, Santa Cruz, 1:500), HNE (recognizes proteins 
modified by the aldehydic lipid peroxidation end product, 4-hydroxynonenal)  (MAB3248, 
R&D Systems, 1:2,000) and β-actin (A5060, Sigma, 1:10,000). Signals were detected using 
species-specific     HRP-conjugated     secondary     antibodies     (Dako)     and     enhanced 
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chemiluminescence and quantified using ImageJ software. Integrated optical density data 
 
were normalized to -actin levels and expressed as relative values. 
 
 
 
 
2.9. Analysis of F2-isoprostanes by GC-MS 
 
 
 
 
Lipid extracts (from ~5 mg tissue) were hydrolysed overnight for GC-MS analysis of F2- 
isoprostanes as described previously (Abbott et al., 2013). Samples were loaded onto pre- 
conditioned solid phase extraction columns (UCT CUQAX223 3 ml; United Chemical 
Technologies, Bristol, USA) and washed with 2ml of 40 mM formic acid (pH 4.5) containing 
40% (v/v) methanol and 2ml hexane/MTBE (1:1). F2-isoprostanes and fatty acids were eluted 
from the SPE columns with MTBE containing 20% methanol and 1% formic acid. The F2- 
isoprostane and fatty acid fraction was dried down under nitrogen and derivatised with 30 µl 
of pentafluorobenzylbromide (PFBBr) (10% in acetonitrile) and 15 µl of N,N- 
diisopropylethylamine (DIPEA) (10% in acetonitrile) at 37°C for 30 min. Excess reagents 
were evaporated under nitrogen. The F2-isoprostane PFBenzyl ester was derivatised with 20 
µl acetonitrile plus 20 µl BSTFA+1% TMCS for 1 hour at 37°C. The derivatised samples 
 
were dried under nitrogen, reconstituted in 40 µl toluene and analysed using an Agilent 
 
7000B triple quadrupole mass selective detector interfaced with an Agilent 7890A GC system 
gas chromatograph, equipped with an automatic sampler and a computer workstation. 
Selected-reaction monitoring (SRM) was performed using the negative chemical ionisation 
(NCI) mode (70eV) with argon as the reagent gas (1.25 ml/min) and the collision gas (0.6 
ml/min). The ion source was maintained at 150°C and the quadrupoles at 150°C. For F2- 
isoprostane analysis, derivatised samples (1 µl) were injected splitless into the GC injection 
port. Column temperature was increased from 180°C to 280°C, at 40°C/min, then to 292°C, 
at 2°C/min, and finally to 305°C, at 50°C/min, with a final hold of 4 min. Quantification of 
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F2-isoprostanes (F2III-ISP + F2VI-ISP) was achieved by comparison of specific SRM 
transitions with their corresponding heavy isotope internal standards. Relative molar response 
factors for each analyte were calculated from calibration curves constructed from different 
concentrations in triplicate, AA and DHA (1 to 25 g) and F2-isoprostanes (0.25 – 2.5 ng), 
and showed good linearity (r2 > 0.98). 
 
 
 
 
2.10. Data analysis 
 
 
 
 
Quantitative data are presented as mean ± SE (represented by the error bars) from 7 to 9 mice 
unless stated otherwise. Statistical differences were assessed using the student’s t-test where 
P < 0.05 was considered significant. 
 
 
 
3. Results 
 
 
 
 
3.1. Generation of APP-PS1 mice that lack apoD or express human apoD in neurons 
 
 
 
 
We   crossed   APP-PS1   mice   with   both   apoD   knockout   (DKO)   and   human   apoD 
overexpressing transgenic (DTG) mice to assess the impact this may have on the amyloid 
phenotype of this AD mouse model. Analysis of murine apoD using PCR methods confirmed 
the absence of apoD mRNA in the brain of APP-PS1/DKO mice (Fig. 1A). The presence of 
human apoD mRNA was similarly confirmed by PCR to be present only in the APP- 
PS1/DTG line (Fig. 1B). The loss of apoD protein was confirmed the APP-PS1/DKO mice 
(Fig. 1C). As previous studies have suggested there may be compensatory changes between 
apoE and apoD in mice (Terrisse et al., 1999) and humans (Kim et al., 2009), possibly due to 
a partial overlap in lipid-binding functions, we also assessed apoE protein levels. ApoD 
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deletion did not significantly alter apoE protein levels, although we did observe a trend (p = 
 
0.06) for 14% lower apoE in the APP-PS1/DKO mice (Fig. 1C and 1E). Further analysis of 
apoE mRNA indicated there was no change associated with apoD loss (Fig. 1F). 
 
 
 
Regarding the APP-PS1/DTG mice, previous studies have confirmed the neuron-specific 
expression of human apoD (under the control of the Thy-1 promoter) in these mice (Do 
Carmo et al., 2008; Ganfornina et al., 2008). This is a valid model for the study of 
neurological disease as even though the vast majority of apoD in the brain is expressed by 
glial cells, under pathological conditions apoD is also detected in neuronal populations (Desai 
et al., 2005; Elliott et al., 2010; Kalman et al., 2000; Rassart et al., 2000). We used an 
antibody that cross-reacts with both mouse and human apoD in order to assess any possible 
 
change in global apoD levels in APP-PS1/DTG mice. The neuronal expression of human 
 
apoD resulted in a modest but statistically significant increase (by 20%) in total apoD protein 
 
levels (Fig. 1D and 1E). Although the presence of apoD in neurons from human apoD 
 
transgenic DTG mice has been previously demonstrated (Do Carmo et al., 2008; Ganfornina 
 
et al., 2008) (and O. Najyb and E. Rassart, unpublished data), we also confirmed this in the 
 
present studies using immunohistochemical techniques. These experiments confirmed that 
 
neuronal apoD was increased in the APP-PS1/DTG mice compared to the APP-PS1 control 
 
mice (Fig. 2). Analysis of the apoD staining indicated the majority of the apoD was neuronal 
 
(although non-neuronal staining was also detected, arrows Fig. 2G-I). Quantitative analysis of 
 
apoD staining indicated a significant overall increase in apoD levels of 21% in the APP- 
 
PS1/DTG mice compared  to  the APP-PS1  control  mice (Fig.  2J).  It  is  noteworthy that 
 
endogenous mouse apoD levels were also higher in the APP-PS1 mice as compared to wild 
 
type  C57Bl6J  mice  (Fig.  2J).  The  total  increase  in  apoD  levels  in  the  APP-PS1/DTG 
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therefore reflects up-regulation of endogenous mouse apoD (in agreement with previous 
 
studies, (Thomas et al., 2001)) and human apoD resulting from transgenic expression. 
 
 
 
 
Neither apoE protein (Fig. 1D and 1E) nor apoE mRNA (Fig. 1F) was altered in the APP- 
PS1/DTG mice compared to control APP-PS1 mice. The APP-PS1/DKO and APP-PS1/DTG 
mice we generated therefore represented an appropriate model to probe for apoD-related 
changes in amyloid pathology that are free of any confounding influences associated with 
altered apoE levels. 
 
 
 
3.2. Deletion of apoD significantly increases amyloid plaque pathology in APP-PS1 mice 
 
 
 
 
The extent of cortical A deposition was assessed in sagittal sections from 11-month-old 
APP-PS1 and APP-PS1/DKO mice using both 6E10 and ThS staining as quantitative markers 
of plaque pathology. Immunohistochemical staining demonstrated numerous 6E10 positive 
 
plaques in the hippocampus and cortex of APP-PS1 mice (Fig. 3A). Hippocampal 6E10 
 
plaque pathology was approximately doubled in the APP-PS1/DKO mice compared to the 
 
APP-PS1 mice (Fig. 3A and 3C). ThS staining was also used as an additional marker of 
amyloid plaque load. ThS binds to -sheet rich structures including components of both 
amyloid plaques and neurofibrillary tangles. ThS staining confirmed that hippocampal plaque 
pathology was significantly increased in the APP-PS1/DKO mice compared to the APP-PS1 
 
control mice (Fig. 3B and 3C). Very similar increases in amyloid plaque and ThS staining 
 
were also detected in the cortex of APP-PS1/DKO as compared to the control APP-PS1 mice 
 
(Fig. 3D). 
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We also used an ELISA method to assess hippocampal levels of soluble Aβ40  and Aβ42  in 
both APP-PS1 mice and APP-PS1/DKO mice. Despite the increase in plaque pathology noted 
above, levels of soluble Aβ40 and Aβ42 were not significantly changed by the loss of apoD in 
 
APP-PS1  mice (Fig.  4A). The pellets  from  the soluble  homogenate  fractions  were also 
 
dissolved in gHCl and assessed by ELISA to give an indicator of “insoluble” Aβ40 and Aβ42 
 
levels. Although a trend for increased levels of Aβ40  was noted (Fig. 4C), this was not 
 
statistically significant. Overall, these data indicate that the deletion of apoD in APP-PS1 
mice results in a significant increase in hippocampal amyloid plaque pathology. 
 
 
 
3.3. Neuronal expression of human apoD significantly decreases amyloid plaque pathology 
in APP-PS1 mice 
 
Using the same suite of techniques utilised in the analysis of plaque pathology in APP- 
PS1/DKO mice, a parallel study focusing on neuronal expression of human apoD in the APP- 
PS1/DTG mice was conducted. In contrast to results arising from apoD deletion, neuronal 
 
expression of human apoD led to a significant reduction in hippocampal and cortical amyloid 
 
plaque pathology as assessed by both 6E10 and ThS staining of the APP-PS1/DTG brain 
 
sagittal sections compared to control APP-PS1 tissues (Fig. 5A-D). Furthermore, levels of 
 
soluble Aβ40  in the APP-PS1/DTG hippocampus were reduced to less than half the level 
 
detected in control APP-PS1 mice (Fig. 4B) and there was a trend (p = 0.077) for a similar 
 
reduction in the insoluble Aβ40 in the same group comparison (Fig 4D). Interestingly, levels 
 
of insoluble (but not soluble) Aβ42 were significantly reduced (by 34%) in the APP-PS1/DTG 
 
mice compared to control APP-PS1 mice (Fig. 4D). The reasons for the selective effect of 
 
apoD overexpression on different A species is not entirely clear. Of potential relevance, it is 
 
known hat the ratio of A42:A40 changes dramatically depending on the stage of amyloid 
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pathology in APP-PS1 mice (Wang et al., 2003). Overall, these data indicate that neuronal 
expression of human apoD significantly decreases hippocampal amyloid plaque pathology in 
APP-PS1 mice. 
 
 
 
3.4. Impact of apoD modulation on APP processing 
 
 
 
 
Based on the significant changes in amyloid plaque load detected in association with 
modulation of apoD levels in the APP-PS1 mouse brain, we went on to assess potential 
alterations in the APP processing pathway that could contribute to these changes. APP is 
sequentially cleaved by - and -secretases to generate A peptides of 39 to 42 amino acids, 
or it may undergo processing via the -secretase pathway which is non-amyloidogenic as the 
-cleavage occurs in the middle of the A sequence and thereby precludes A generation (De 
 
Strooper et al., 2010; Kang et al., 1987). During these proteolytic steps, membrane associated 
APP C-terminal fragments (CTFs) are generated that, along with an analysis of full length 
APP, can be used as a de facto measure of changes in the rate of APP proteolytic processing 
in the brain. The major APP CTFs formed result from: the -cleavage, referred to as the 
 
“C83” CTF; the -(BACE1)-cleavage, referred to as the “C99” CTF; and, at lower levels, the 
 
-secretase products of both C83 and C99 cleavage, referred to as the APP intracellular 
 
domain (AICD) fragment. The major APP CTF fragments used for quantification in the 
 
present study have an apparent MW of 9 kDa and 12 kDa, consistent with C83 and C99, 
 
respectively. The western blot bands we used for quantification are thus outlined on the full- 
 
length western blots included as supplementary data (Suppl. Fig. 1). Comparing the APP-PS1 
 
and  APP-PS1/DKO  mice  (Fig.  6A  and  6C),  the  levels  APP  CTFs  were  found  to  be 
 
significantly increased (by 44%). This was associated with significantly increased (by ~2- 
 
fold) levels of BACE1 in the APP-PS1/DKO mice (Fig. 6B and 6C). Note that the increased 
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BACE1 in the APP-PS1/DKO mice was not likely to be due to the deletion of apoD per se, as 
 
BACE1 levels were essentially identical when  WT and  apoD null mice were compared 
 
(Suppl. Fig 2).  Based on these results, we also assessed the same tissues for CTFs derived 
from BACE1-mediated cleavage of neuregulin-1 (NRG1), another well characterized BACE1 
substrate (Fleck et al., 2012; Fleck et al., 2013; Hu et al., 2006). In this case, we detected a 
 
significant 27% increase in NRG1 CTFs in the APP-PS1/DKO mice (Fig. 6B and 6C). 
 
 
 
Expression levels of these same proteins were also investigated in the brain homogenates 
derived from the APP-PS1/DTG mice. Intriguingly, and in contrast to the data derived from 
the APP-PS1/DKO mouse study, we found that the levels of APP CTFs were significantly 
 
reduced (by 40%) in the APP-PS1/DTG mice (Fig. 6D and 6F). Non-significant trends for 
 
decreased levels of BACE1 and NRG1 CTFs were also apparent (Fig. 6E and 6F). Although 
not  statistically  significant  across  all  parameters,  these  data  point  towards  an  inverse 
association between apoD levels and BACE1 levels / activity in the brain. 
 
 
 
 
To gain additional information regarding the potential modulation of BACE1 expression in 
 
the hippocampus, tissue sections were immunostained and the intensity of staining quantified. 
 
BACE1 appeared to be strongly expressed in the CA3 region of the hippocampus in all mice 
 
studied (Fig. 7). We also detected increased BACE1 staining in the vicinity of amyloid 
 
plaques as a general phenomenon across all mouse groups (typical examples are provided in 
 
Supplemental Figure 3). The quantitative analysis indicated hippocampal BACE1 levels were 
 
significantly  increased  by  25%  in  the  APP-PS1/DKO  mice  compared  to  the  APP-PS1 
 
controls, whereas no change in BACE1 staining level was detected in the APP-PS1/DTG 
 
mice compared to the APP-PS1 controls (Fig. 7B). These data are in agreement with the 
 
western blot analysis of BACE1 (Fig. 6). As alterations in amyloid plaque pathology may be 
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associated with gliosis (Yan et al., 2009), we also assessed potential changes in glial markers 
 
GFAP (astrocytes) and Iba1 (microglia). An increase in hippocampal Iba1 (but not GFAP) 
 
staining was detected in APP-PS1/DKO mice compared to the APP-PS1 controls (Fig. 7), 
 
whereas  no  changes  in  either  Iba1  or  GFAP  were  detected in  the  APP-PS1/DTG mice 
 
compared to the APP-PS1 controls (Fig. 7). Colocalization immunohistochemical studies 
 
indicated that BACE1, GFAP and Iba1 staining were all clearly detected in the vicinity of 
 
amyloid plaques (Suppl. Fig. 3). It is therefore possible that at least part of the modulation of 
 
BACE1 levels is a response to the development of amyloid pathology. Consistent with this 
 
notion, there is evidence to suggest that a vicious cycle exists whereby A and BACE1 both 
 
reciprocally up-regulate each others expression levels (Chami and Checler, 2012). 
 
 
 
 
3.5. Impact of apoD modulation on markers of lipid peroxidation 
 
 
 
 
Increased brain lipid peroxidation is associated with AD and is also a feature of AD mouse 
models, including the APP-PS1 line (Abdul et al., 2008; Markesbery and Carney, 1999). 
Based on the knowledge that apoD plays a significant role in protecting against lipid 
peroxidation in the brain (Ganfornina et al., 2008), we also assessed the mouse brain tissues 
for two markers of lipid peroxidation, HNE-modified proteins and F2-isoprostanes. We 
previously reported that HNE-modified proteins in the range of ~56 kDa were positively 
associated with age in the human brain and inversely correlated with apoD expression (Kim 
et al., 2009), therefore similar protein markers were the focus in the present study. Although 
 
trends consistent with a lipid antioxidant function of apoD were noted (Fig. 8), no statistically 
significant changes in the abovementioned lipid peroxidation markers were detected. Altered 
lipid oxidation status therefore does not appear to be a major contributing factor in the altered 
AD pathology we have described in association with brain apoD levels in the APP-PS1 
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mouse model herein. Furthermore, the significant changes in plaque pathology associated 
with altered apoD expression we report do not appear to significantly modify brain lipid 
oxidation status. 
 
 
 
4. Discussion 
 
 
 
 
 
ApoD is a 29 kDa glycoprotein member of the lipocalin family (Rassart et al., 2000). The 
apoD crystal structure reveals an eight-stranded antiparallel -barrel flanked by an -helix 
(Eichinger et al., 2007). The -barrel encloses a conically shaped hydrophobic cavity referred 
to as the apoD ligand binding pocket. Early studies suggested that apoD binds a range of 
lipids including arachidonic acid (AA), cholesterol and several steroids (Dilley et al., 1990; 
Lea, 1988; Morais Cabral et al., 1995; Pearlman et al., 1973). More recent studies indicate 
that binding of lipids in the apoD binding pocket is in fact quite specific (Eichinger et al., 
2007; Oakley et al., 2012; Vogt and Skerra, 2001). Progesterone, AA and retinoic acid bind 
to the apoD binding pocket with high affinity whereas pregnenolone and specific eicosanoids 
(e.g. 12-HETE and 5,15-diHETE) also bind but with reduced affinity (Dilley et al., 1990; 
Lea, 1988; Morais Cabral et al., 1995; Ruiz et al., 2013). In addition to the binding pocket, 
apoD may also interact with lipids via a cluster of “exposed” hydrophobic residues residing 
in 3 of its extended loops (Eichinger et al., 2007; Oakley et al., 2012). These exposed 
residues generate a region of surface hydrophobicity close to the open end of the binding 
pocket that facilitates apoD association with high-density lipoprotein (HDL) particles and is 
also thought to permit insertion of apoD into cellular lipid membranes (Eichinger et al., 
2007). 
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Several previous studies have shown that apoD levels are up-regulated in the AD brain 
(Bhatia et al., 2013; Terrisse et al., 1998; Thomas et al., 2003; Thomas et al., 2001), that there 
is a marked increase of neuronal apoD expression in AD (Desai et al., 2005; Kalman et al., 
2000), and that apoD is found in amyloid plaques (Desai et al., 2005). Three studies have also 
reported associations between variations in the APOD gene and AD risk (Chen et al., 2008; 
Desai et al., 2003; Helisalmi et al., 2004). However, the direct role that apoD may play in 
modulating the course of AD has not been previously addressed. Our findings provide the 
 
first  evidence that  apoD expression  levels  do  influence amyloid  plaque pathology.  It  is 
 
intriguing that neuronal apoD expression is induced in human AD and in AD mouse models, 
 
yet a further increase, as achieved by transgenic neuronal expression in our current studies, is 
 
still able to significantly reduce amyloid plaque pathology. A similar outcome has also been 
 
reported in other studies using the same experimental approach to understand the function of 
 
proteins that may be involved in the regulation of AD pathology. For example, expression of 
 
the lipid transport protein ATP-binding cassette transporter A1 (ABCA1) is increased in the 
 
brain in human AD and AD mouse models (Kim et al., 2010), yet transgenic expression of 
 
ABCA1 in AD mice significantly reduces plaque pathology (Wahrle et al., 2008). It may be 
 
that for apoD, and other “protective” proteins like ABCA1, the homeostatic increase in 
 
protein expression is only partially protective, or is protective only later in the disease process 
 
when the up-regulation is stimulated in response to pathogenic stimuli. In contrast, transgenic 
 
expression of the protective protein could provide optimal protection through all stages of life 
 
and AD development, thus resulting in greater therapeutic efficacy. 
 
 
 
 
Loss-of-function Drosophila mutants for the apoD homolog glial lazarillo (GLaz) were more 
sensitive to oxidative stress and contained higher concentrations of lipid peroxidation 
products;  suggesting  a  function  for  apoD/GLaz  in  lipid  peroxide  (L-OOH)  scavenging 
22 
(Sanchez et al., 2006). In agreement with this, over-expression of GLaz in transgenic 
Drosophila lines resulted in an increased resistance to oxidative stress, a 29% extension in 
lifespan and protection against hyperoxia-induced behavioural decline (Walker et al., 2006). 
In addition, expression of human apoD reduced the accumulation of aldehydic end-products 
of lipid peroxidation in old flies (Muffat et al., 2008). Similarly, the expression of human 
apoD in mouse neurons provided protection against paraquat-induced brain lipid peroxidation 
(Ganfornina et al., 2008). Since apoD provides lipid antioxidant protection in the brain 
(Ganfornina  et  al.,  2008),  one  plausible  mechanistic  explanation  could  be  due  to  the 
secondary regulation of A production by brain lipid oxidation products. Previous studies 
have shown that oxidative stress and the products of lipid peroxidation, HNE in particular, 
up-regulate the expression of BACE1 leading to increased neuronal A production (Paola et 
al., 2000; Tamagno et al., 2005). This would be consistent with the increase in BACE1 
protein  levels  we  observed  in  the  APP-PS1/DKO  mice  as  compared  to  their  APP-PS1 
 
littermates (Fig. 6). Although the converse (i.e. reduced BACE1) was not observed in the 
 
APP-PS1/DTG experiment, a decrease in APP CTFs including the BACE1 product (C99) 
 
was detected (Fig. 6). This provides initial evidence that the modulation of A pathology by 
 
apoD may be mediated by BACE1. The precise mechanisms by which apoD modulates AD 
 
pathology remain to be resolved and, based on our current findings, this is an area that 
 
appears to warrant further investigation. 
 
 
 
 
One limitation in our study is that we have not assessed additional groups of animals at 
 
earlier times points. Such future studies might reveal if BACE1 modulation plays a role in the 
 
earlier stage during development of AD pathology. Also related to this, at the time of animal 
 
cull at 11 months (a time chosen to ensure reasonable plaque load was present in all APP-PS1 
 
mice), we detected only non-significant trends in HNE and F2-isoprostane markers of lipid 
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peroxidation  (Fig.  8).  It  is  possible  that  with  advancing  stages  of  plaque  pathology,  a 
 
response to the predicted oxidative stress can be mounted that is sufficient to “normalise” the 
 
lipid oxidative damage. We have shown previously in studies of post-mortem human brain 
 
that  there  is  a  coordinated  up-regulation  of  apoD  and  additional  antioxidant  enzymes 
 
(superoxide dismutase 1 and glutathione peroxidase 3) associated with aging and increased 
 
levels of HNE-modified proteins (Kim et al., 2009). Follow up studies that focus on early 
 
time points of amyloid pathology development in these mice may add additional mechanistic 
 
insights. 
 
 
 
 
ApoD may also regulate AD pathology via modulation of eicosanoids such as 5s-, 12s- and 
 
15s-hydroperoxyeicosatetraenoic acids (HpETEs) that play a key role in brain inflammatory 
pathways (Phillis et al., 2006), and have been shown to be regulated by apoD in vitro (Bhatia 
et al., 2012; Oakley et al., 2012). Altered eicosanoid metabolism would be predicted to have 
significant  impact  on  neuronal  signalling  and  neuroinflammation  in  the  AD  context 
(Sanchez-Mejia and Mucke, 2010). Furthermore, pro-inflammatory conditions induced by 
lipopolysaccharide (LPS) have been shown to increase apoD expression in a time- and dose- 
dependent manner and the elements in the apoD promoter responsible (NF-B, AP-1 and 
APRE-3) were confirmed to all be involved in the inflammatory response (Do Carmo et al., 
2007). ApoD may also have an impact on the inflammatory pathways associated with AD 
pathology via regulation of specific cytokines. Previous studies in the Thy-1/ApoD (DTG) 
mice indicate that apoD protects against viral encephalitis by reducing both TNF and IL1 
expression and increasing IL6 expression (Do Carmo et al., 2008). This could potentially tie 
in with the concept regarding modulation of eicosanoid metabolism by apoD, as DTG mice 
have reduced phospholipase-A2 (PLA2) activity in the brain (Do Carmo et al., 2008). Based 
on the facts that: (i), PLA2 is required to release arachidonic acid form phospholipids to 
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provide substrates for bioactive eicosanoids (Sanchez-Mejia and Mucke, 2010); (ii), PLA2 is 
up-regulated by TNF and IL1 (Adibhatla and Hatcher, 2007); (iii), that inflammation 
promotes A  production and exacerbates amyloid plaque pathology (Sastre et al., 2003; 
Sastre et al., 2008; Yamamoto et al., 2007), it is reasonable to expect that apoD may regulate 
AD progression via such anti-inflammatory processes. In a preliminary screen, however, we 
did not detect changes in cortical levels of TNF or IL in either the APP-PS1/DKO or APP- 
PS1/DTG mice compared to their APP-PS1 littermates (H. Li, S. Sanz Muñoz and B. Garner, 
unpublished data). Interestingly, both of the proposed mechanisms by which apoD may 
regulate amyloid plaque pathology (i.e. oxidative stress and inflammation) intersect at the 
BACE1 nexus (Chami and Checler, 2012). 
 
 
 
In summary, the current studies using both gene knockout and neuronal overexpression 
approaches provide clear evidence that apoD regulates amyloid plaque pathology in a mouse 
model of AD. The role that apoD plays in the regulation of lipid oxidative stress, and 
neuroinflammation and the impact this has on BACE1-dependent and -independent pathways 
contributing to AD pathology is an area that appears to warrant further study. 
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FIGURE LEGENDS 
 
 
 
 
Fig. 1. Generation of APP-PS1/DKO and APP-PS1/DTG mice. APP-PS1/DKO mice and 
APP-PS1/DTG mice that either lack apoD or express human apoD in neurons, respectively, 
were generated as described in the “Materials and Methods” section. Cortical samples were 
assessed for mouse apoD mRNA (A) and human apoD mRNA (B) with each compared to the 
appropriate APP-PS1 littermate control mice (A, B). ApoD and apoE protein levels were 
assessed by western blotting and -actin was used as a loading control (C, D). Relative 
protein and mRNA levels (where appropriate) were quantified using optical density of the 
scanned gels/blots (E, F). Representative samples are shown in the gels/blots. Quantitative 
 
data are means of 7 to 9 samples with the SE shown by the error bars. * P < 0.05; *** P < 
 
0.0001; # trend, P = 0.05 to 0.06. 
 
 
 
 
Fig.  2.  ApoD  immunohistochemical  analysis  in  APP-PS1  and  APP-PS1/DTG  mice. 
 
Sagittal sections from wild type (WT), APP-PS1 and APP-PS1/DTG cortex were stained for 
 
apoD and NeuN to assess the extent of neuronal apoD localization. ApoD staining intensity 
 
was assessed using Image J software and the data expressed relative to the WT mice that 
 
were assigned an arbitrary relative plaque value of 1.0 (C). The white arrows indicate non- 
 
neuronal staining. Quantitative data are means of 3 to 4 samples with the SE shown by the 
 
error bars. ** P < 0.05 (for comparison of APP-PS1 and APP-PS1/DTG apoD staining). 
 
Scale bar in “F” = 200 m. Scale bar in “I” = 20 m. 
 
 
 
 
Fig. 3. Impact of apoD loss on amyloid plaque pathology in APP-PS1 mice. Sagittal 
sections from APP-PS1 and APP-PS1/DKO mice were stained with 6E10 (A) or ThS (B) to 
assess  amyloid  plaque  load.  The  area  fraction  of  the  hippocampal  and  cortical  regions 
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occupied by plaques was calculated using Image J software and the data expressed as plaque 
levels relative to the APP/PS1 mice that were assigned an arbitrary relative plaque value of 
1.0 (C-D). Grey bars, APP-PS1 group; black bars, APP-PS1/DKO group. Scale bars = 500 
 
m. All quantitative data are expressed as mean ± SE (represented by the error bars). * P < 
 
0.05, ** P < 0.01. 
 
 
 
 
Fig. 4. Impact of apoD modulation on soluble and insoluble A species. Quantification of 
 
Aβ40   and Aβ42   levels  in  APP-PS1/DKO  and  APP-PS1/DTG  hippocampal  homogenates, 
 
relative to their appropriate APP-PS1 control mouse groups, was assessed by ELISA. For all 
 
samples, the “soluble” (A-B) and “insoluble” (guanidine HCl solubilised) A species were 
 
quantified. Grey bars, APP-PS1 group; black bars, APP-PS1/DKO (DKO) or APP-PS1/DTG 
 
(DTG) group, as indicated. Scale bars = 500 m. All quantitative data are expressed as mean 
 
± SE (represented by the error bars). * P < 0.05, ** P < 0.01, #  P = 0.08 (non-significant 
 
trend). 
 
 
 
 
Fig. 5. Impact of transgenic neuronal expression of human apoD on amyloid plaque 
pathology in APP-PS1 mice. Sagittal sections from APP-PS1 and APP-PS1/DTG mice were 
stained with 6E10 (A) or ThS (B) to assess amyloid plaque load. The area fraction of the 
hippocampal region occupied by plaques was calculated using Image J software and the data 
expressed as plaque levels relative to the APP/PS1 mice that were assigned an arbitrary 
relative plaque value of 1.0 (C). Grey bars, APP-PS1 group; black bars, APP-PS1/DTG 
group. Scale bars = 500 m. All quantitative data are expressed as mean ± SE (represented by 
the error bars). * P < 0.05, ** P < 0.01. 
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Fig. 6. Impact of apoD modulation on APP processing. Hippocampal homogenates derived 
from APP-PS1/DKO, APP-PS1/DTG and their appropriate control APP-PS1 groups were 
probed for the proteins listed by western blotting (A, B, D, E). Representative blots (n = 4 to 
5 samples for each group) are shown. -Actin is used as a loading control. Integrated optical 
density for blots of all samples is shown (C, F). Grey bars, APP-PS1 group; black bars, APP- 
PS1/DKO or APP-PS1/DTG group. Levels are expressed relative to APP-PS1 mice and 
presented as mean + SE. * P < 0.05, *** P < 0.0001. APP, amyloid precursor protein; CTFs, 
APP  C-terminal  fragments;  BACE1,  beta-site  APP  cleaving  enzyme-1;  NRG1  CTFs, 
 
neuregulin-1 C-terminal fragments. Note that consistent with previous data (Ghosal et al., 
 
2009), the major APP CTFs are tentatively assigned as C99 (CTF, 12 kDa) and C83 (CTF, 
 
9.2 kDa). The identity of a third apparent APP CTF band at ~15 kDa is unknown and its 
 
levels were not used in the data presented (although inclusion of this band in the analysis did 
 
not alter the data). For quantification, the optical density of the two major APP CTF bands 
 
were measured together. Full-length western blots related to APP CTF proteolytic products 
 
are provided in Supplementary materials (Suppl. Fig. 1). 
 
 
 
 
Fig. 7. Impact of apoD modulation on hippocampal BACE1, GFAP, and Iba1 levels 
 
assessed  by  immunohistochemistry.  Sagittal  sections  from  APP-PS1/DKO  and  APP- 
 
PS1/DTG  mice  and  their  appropriate  control  APP-PS1  groups  were  immunostained  for 
 
BACE1, GFAP and Iba1 (A), and the staining intensity quantified using ImageJ software. 
 
The data are presented as protein levels relative to the APP/PS1 mice that were assigned an 
 
arbitrary relative value of 1.0 (B). Grey bars, APP-PS1 group; black bars, APP-PS1/DKO 
 
(DKO) or APP-PS1/DTG (DTG) group. Statistical differences are expressed relative to APP- 
 
PS1 control mice and data presented as mean + SE, n = 4 to 5 sections per group. * P < 0.05. 
 
Scale bar = 500 m. 
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Fig. 8. Impact of apoD modulation on markers of lipid oxidative stress. Brain 
homogenates  derived  from  APP-PS1/DKO,  APP-PS1/DTG  and  their  appropriate  control 
APP-PS1 groups were probed for the proteins modified by the lipid peroxidation aldehydic 
product 4-hydroxynonenal (HNE) by western blotting (A, B). Representative blots (n = 4 to 7 
samples for each group) are shown. -Actin is used as a loading control. Integrated optical 
density for blots of all samples is shown (C). Grey bars, APP-PS1 group; black bars, APP- 
PS1/DKO or APP-PS1/DTG group. Comparison of F2-isoprostane levels in APP-PS1/DKO 
or APP-PS1/DTG groups and their appropriate control APP-PS1 groups. Lipids were 
extracted, the F2-isoprostane fraction was purified by solid phase extraction and F2- 
isoprostane PFBenzyl esters were prepared and derivatised with BSTFA and TMCS for 
analysis using GC-MS. The F2-isoprostanes were quantified by comparison to internal 
standards. Data are expressed as pg F2-isoprostane per g of arachidonic acid (AA). Levels 
are expressed relative to APP-PS1 mice and presented as mean + SE. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
 
 
 
Suppl. Fig. 1. Impact of apoD modulation on APP processing –  full length western blots 
 
demonstrating position of APP CTFs. Hippocampal homogenates derived from APP- 
 
PS1/DKO, APP-PS1/DTG and their appropriate control APP-PS1 groups were probed for the 
 
APP and APP proteolytic products. The region marked as “CTFs” represent the panels that 
 
are shown for APP CTFs in Fig. 6. Note that consistent with previous data (Ghosal et al., 
 
2009), the major APP CTFs are tentatively assigned as C99 (CTF, 12 kDa) and C83 (CTF, 
 
9.2 kDa). The identity of a third apparent APP CTF band at ~15 kDa is unknown and its 
 
levels were not used in the data presented (although inclusion of this band in the analysis did 
 
not alter the data). For quantification, the optical density of the two major APP CTF bands 
 
were measured together (shown by the dashed red line boxes in the blots on the right hand 
 
side). APP, amyloid precursor protein; CTFs, APP C-terminal fragments. 
 
 
 
 
Suppl. Fig. 2. Hippocampal BACE1 expression is not altered in apoD null mice. 
 
Hippocampal homogenates derived from wild type (WT) and apoD null (apoD-/-) mice (in the 
 
absence of the APP-PS1 background) were probed for apoD, BACE1, and -actin by western 
 
blotting. The representative blots indicate no change in BACE1 levels in either male of 
 
female apoD-/-mice as compared to WT control mice. 
 
 
 
 
Suppl. Fig. 3. Distribution pattern of hippocampal BACE1, GFAP and IBa1 with 
 
amyloid plaques by double-staining immunofluorescence. Sagittal sections from brains of 
 
APP-PS1/DKO mice were used for double-labelling with an A antibody and a BACE1 
 
antibody to demonstrate the distribution of BACE1 and its relationships with amyloid plaque 
 
(A). The confocal images demonstrate that BACE1 is localize around WO2-positive plaques 
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and in the CA3 region where the highest BACE1 level is detected. Staining for glial markers 
 
GFAP (astrocytes) and Iba1 (microglia) close to the hippocampal CA3 region also 
 
demonstrated a close association of these glial markers around WO2-positive plaques (B). 
 
Scale bar in “A” = 500 m, scale bars in “B” = 100 m. 
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Research highlights 
 
-  Brain apoD levels are increased with aging and Alzheimer’s disease 
-  It was unclear if apoD modulates amyloid pathology in vivo 
-  ApoD deletion exacerbated amyloid pathology in the APP/PS1 mice 
-  Transgenic neuronal apoD expression reduced amyloid pathology in the 
APP/PS1 mice 
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